• Submit to Pharmaceutics Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• For Librarians
• About
• Open Access Policy

• Abstract
• Full-Text PDF [232 KB]

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Muhlack, S
• Müsch, P
• Konietzka, S
• Woitalla, D
• Przuntek, H
• Müller, T
• [+] on Google Scholar
• Muhlack, S
• Müsch, P
• Konietzka, S
• Woitalla, D
• Przuntek, H
• Müller, T
• [+] on PubMed
• Muhlack, S
• Müsch, P
• Konietzka, S
• Woitalla, D
• Przuntek, H
• Müller, T

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter
• More services

Open AccessThis article is

• freely available
• re-usable

Pharmaceutics 2010, 2(3), 313-320; doi:10.3390/pharmaceutics2030313

Article

Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease

Siegfried Muhlack, Patricia Müsch, Sandra Konietzka, Dirk Woitalla, Horst Przuntek and Thomas Müller *

Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany

* Author to whom correspondence should be addressed.

Received: 1 June 2010; in revised form: 26 August 2010 / Accepted: 14 September 2010 / Published: 20 September 2010

Download PDF Full-Text [232 KB, uploaded 20 September 2010 16:51 CEST]

Abstract: Application of oral fast release amantadine and levodopa may induce an improvement of motor symptoms in patients with Parkinson’s disease (PD). The objective of this trial was to investigate the clinical efficacy of a fast release amantadine sulfate formulation on simple and complex movement performance and putative relations to the pharmacokinetic behavior in PD patients. We challenged two cohorts of 12 PD patients, who were taken off their regular antiparkinsonian treatment for at least 12 hours, with oral 300 mg amantadine sulfate. We scored motor symptoms and performed instrumental tasks, which ask for performance of simple or complex motion series under cued conditions. Motor symptoms and performance of complex movements significantly improved in contrast to the carrying-out of simple motions. N-methyl-D-aspartic acid antagonistic and dopaminomimetic amantadine also influences altered higher predominant prefrontal cognitive functions. Therefore, performance of complex motion series improved, whereas carrying-out of simple repetitive movements is more associated to the striatal dopamine dependent basal ganglia function.

Keywords: Parkinson’s disease; amantadine; motion; cognition

Article Statistics

Cite This Article